Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF) Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prognostic Value of Left Atrial Functional Measures in Heart Failure With Reduced Ejection Fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Right ventricular and pulmonary vascular function are influenced by age and volume expansion in healthy humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk Factors for Morbidity and Mortality Following Hospitalization for Pericarditis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Clinical presentation and outcomes in women and men with advanced heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Gerd Hasenfuss
  • Finn Gustafsson
  • David Kaye
  • Sanjiv J Shah
  • Dan Burkhoff
  • Marie-Christine Reymond
  • Jan Komtebedde
  • Mark Hünlich
  • Reduce LAP-HF Trial Investigators
Vis graf over relationer

OBJECTIVE: Heart failure with preserved ejection fraction (HFpEF) is characterized by elevated left atrial pressure during rest and/or exercise. The Reduce LAP-HF (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure) trial will evaluate the safety and performance of the Interatrial Shunt Device (IASD) System II, designed to directly reduce elevated left atrial pressure, in patients with HFpEF.

METHODS: The Reduce LAP-HF Trial is a prospective, nonrandomized, open-label trial to evaluate a novel device that creates a small permanent shunt at the level of the atria. A minimum of 60 patients with ejection fraction ≥40% and New York Heart Association functional class III or IV heart failure with a pulmonary capillary wedge pressure (PCWP) ≥15 mm Hg at rest or ≥25 mm Hg during supine bike exercise will be implanted with an IASD System II, and followed for 6 months to assess the primary and secondary end points. Safety and standard clinical follow-up will continue through 3 years after implantation. Primary outcome measures for safety are periprocedural and 6-month major adverse cardiac and cerebrovascular events (MACCE) and systemic embolic events (excluding pulmonary thromboembolism). MACCE include death, stroke, myocardial infarction, or requirement of implant removal. Primary outcome measures for device performance include success of device implantation, reduction of PCWP at rest and during exercise, and demonstration of left-to-right flow through the device. Key secondary end points include exercise tolerance, quality of life, and the incidence of heart failure hospitalization.

CONCLUSION: Reduce LAP-HF is the first trial intended to lower left atrial pressure in HFpEF by means of creating a permanent shunt through the atrial septum with the use of a device. Although the trial is primarily designed to study safety and device performance, we also test the pathophysiologic hypothesis that reduction of left atrial pressure will improve symptoms and quality of life in patients with HFpEF.

OriginalsprogEngelsk
TidsskriftJournal of Cardiac Failure
Vol/bind21
Udgave nummer7
Sider (fra-til)594-600
Antal sider7
ISSN1071-9164
DOI
StatusUdgivet - jul. 2015

ID: 46172834